ABVC BioPharma, Inc. (NASDAQ: ABVC) has reported a transformative fiscal year 2025, with total assets increasing 179% to $21,062,203 from $7,539,907 in 2024. The growth was primarily fueled by strategic land acquisitions in Asia, signaling a shift toward a hybrid asset-backed licensing model. The company filed its Annual Report on Form 10-K for the year ended December 31, 2025, highlighting a substantial balance sheet expansion and long-term asset positioning.
Net property and equipment rose to $12,835,409, up from $511,088 in the prior year, largely due to the acquisition of land and development-oriented assets in Taiwan. As of December 31, 2025, the company also reported operating lease right-of-use assets of $1.91 million and long-term investments of $1.88 million. Management views the 2025 fiscal year as a structural strengthening of the company's balance sheet and asset foundation.
ABVC's licensing structure has been central to its strategy. The company has licensed its core drug programs to subsidiaries and related parties: the CNS pipeline to AiBtl BioPharma, oncology programs to OncoX BioPharma, and ophthalmology programs to ForSeeCon Eye Corporation. This model allows subsidiaries to handle clinical development, reducing ABVC's direct cash burn while retaining licensing economics and equity participation. The approach separates development risk from long-term value participation, mitigating capital intensity.
In parallel, ABVC is strengthening its infrastructure in Asia through direct and subsidiary land acquisitions. In Longtan District, Taoyuan, a 5,995.41 square meter property valued at $4.6 million is held as a strategic reserve with potential healthcare or biotechnology applications. In Puli Township, Nantou, a 69,230.90 square meter property appraised at approximately $8.0 million is planned for a staged development including a medicinal plant cultivation base, pharmaceutical supply chain localization, and agricultural-biotech integration. The Puli site's projected annual cultivation output is estimated between $60,000 to $360,000 depending on processing depth. Both land title transfers are under government review.
This evolution toward a hybrid asset model combines intellectual property, licensing revenue potential, equity participation in development subsidiaries, and tangible physical assets. ABVC BioPharma is a clinical-stage biopharmaceutical company with a pipeline of six drugs and one medical device (ABV-1701/Vitargus®). The company utilizes in-licensed technology from research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center.
Forward-looking statements in the press release are subject to risks and uncertainties detailed in the company's SEC filings, available at http://www.sec.gov.
